✦ LIBER ✦

904 INITIAL RESULTS FROM PHASE I/II TRIAL WITH DENDRITIC CELLS LOADED WITH AN ALLOGENEIC PROSTATE CANCER-LYSATE IN HORMONE-REFRACTORY PROSTATE CANCER PATIENTS

✍ Scribed by P. Reyes; M.N. Lopez; C. Pereda; R. Aguilera; F. Salazar-Onfray

Book ID: 119621622
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 80 KB
Volume: 9
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(10)60885-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

VACCINATION OF HORMONE-REFRACTORY PROSTA

VACCINATION OF HORMONE-REFRACTORY PROSTATE CANCER PATIENTS WITH PEPTIDE COCKTAIL-LOADED DENDRITIC CELLS: RESULTS OF A PHASE I CLINICAL TRIAL

✍ S. Füssel; A. Meye; M. Schmitz; S. Zastrow; C. Linné; K. Richter; B. Lobel; O.W. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 42 KB

VACCINATION OF HORMONE-REFRACTORY PROSTA

VACCINATION OF HORMONE-REFRACTORY PROSTATE CANCER PATIENTS WITH PEPTIDE COCKTAIL-LOADED DENDRITIC CELLS: CLINICAL RESULTS OF A PHASE I CLINICAL TRIAL

✍ O. Hakenberg; S. Fuessel; A. Meye; M. Schmitz; S. Zastrow; K. Richter; P. Rieber 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 63 KB

Re: Vaccination of Hormone-Refractory Pr

Re: Vaccination of Hormone-Refractory Prostate Cancer Patients with Peptide Cocktail-Loaded Dendritic Cells: Results of a Phase 1 Clinical Trial

✍ Hans-Peter Schmid 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 43 KB

VACCINATION OF HORMONE-REFRACTORY PROSTA

VACCINATION OF HORMONE-REFRACTORY PROSTATE CANCER PATIENTS WITH PEPTIDE COCKTAIL-LOADED DENDRITIC CELLS: IMMUNOLOGICAL RESULTS OF A PHASE 1 CLINICAL TRIAL

✍ S. Fuessel; M. Schmitz; K. Richter; A. Meye; S. Zastrow; C. Linné; O.W. Hakenber 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Results from a pilot Phase I trial of ge

Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer

✍ George Wilding; Patrick Soulie; Donald Trump; Ashis Das-Gupta; Eric Small 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

Allogeneic retrovirally transduced, IL-2

Allogeneic retrovirally transduced, IL-2- and IFN-γ-secreting cancer cell vaccine in patients with hormone refractory prostate cancer—a phase I clinical trial

✍ T. H. Brill; H. R. Kübler; H. v. Randenborgh; F. Fend; H. Pohla; J. Breul; R. Ha 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 856 KB

## Abstract ## Background The purpose of this vaccine study was to determine the safety and feasibility of vaccination with an allogeneic prostate carcinoma cell line, LNCaP, expressing recombinant interleukin‐2 (IL‐2) and interferon‐γ (IFN‐γ) and to evaluate the efficacy of inducing tumor‐specifi